Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-06
1997-01-21
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514562, 514665, 514912, A61K 31425, A61K 31195, A61K 3113
Patent
active
055960111
ABSTRACT:
Macular degeneration is an age-related eye disease for which there is no known treatment to date that has been shown to be effective at treating or preventing the onset or progression of the disease. Current treatment of non-exudative (dry form) macular degeneration is limited to early diagnosis and careful followup, while symptomatic treatment of exudative (wet form) macular degeneration includes laser photocoagulation therapy, surgery, low dose radiation (teletherapy), and anti-oxidant or anti-inflammatory therapies. The present invention relates to a new method for treating or preventing the onset or progression of macular degeneration, comprising periodic administration of a glutathione (GSH) enhancing agent alone or in conjunction with at least one of an anti-oxidant or an anti-inflammatory therapy, and possibly in addition to one or more of the symptomatic treatments mentioned above.
REFERENCES:
S. H. Sarks, John P. Sarks, Age-Related Macular Degeneration: Atrophic Form, vol. Two, Macular Disease, Chapter 64, 1989, pp. 149-173.
S. West et al., Are Antioxidants or Supplements Protective for Age-Related Macular Degeneration?, Archives of Ophthalmology, Feb. 1994, pp. 222-227.
M. M. E. Bridgeman et al., Cysteine and Glutathione Concentrations in Plasma and Bronchoalveolar Lavage Fluid (1991) after Treatment with N-Acetylcysteine, Dept. of Biochemistry, U. of Edinburgh, Medical School, pp. 39-42.
M. M. E. Bridgeman, et al., Effect of N-Acetyl Cysteine on the Concentrations of Thiols in Plasma, Bronchoalveolar Lavage Fluid, and Lung Tissue, Dept. of Biochemistry, U. of Edinburgh Med. School, 1994, pp. 670-675.
B. de Quay et al., Glutathione Depletion in HIV-Infected Patients: Role of Cysteine Deficiency and Effect of Oral N-Acetylcysteine, Current Science Ltd., 1992, pp. 875-876.
Wayne E. Fung, Interferon Alpha 2a for Treatment of Age-Related Macular Degeneration, American Jounal of Ophthalmology, Sep. 1991, pp. 349-350.
W. de Backer, Inflammatory Mediators in Acute Lung Injury and Copd: Effects of N-Acetylcysteine, Pulmo script, Sep. 1994.
G. R. Bernard, N-Acetylcysteine in Experimental and Clinical Acute Lung Injury, The American Journal of Medicine, Sep. 1991.
O. I. Aruoma et al., The Antioxidant Action of N-Acetylcysteine: Its Reaction with Hydrogen Perioxide, Hydroxyl Radical, Superoxide, and Hypochlorous Acid, Free Radical Biology & Medicine, 1989, pp. 593-597.
I. H. Chisholm, The Prospects for New Treatments in Age-Related Macular Degeneration, British Journal of Ophthalmology, 1993.
P. Ko et al, Understanding Macular Degeneration, Hospital Medicine, Sep. 1994, pp. 47-55.
J. M. Seddon et al, Vitamins, Minerals, and Macular Degeneration, Archives of Ophthalmology, 1994, pp. 176-179.
Repine John E.
Repine Karen M.
LandOfFree
Method for the treatment of macular degeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of macular degeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of macular degeneration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2324509